ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

solbinsiran

Also written as “LY3561774” and “Solbinsiran”.

In Eli Lilly’s own words, LY3561774 (Solbinsiran) is a GalNAc-conjugated mRNA silencing agent that specifically targets ANGPTL3 expression in the liver.. Its studies are mostly in Hypertriglyceridemia · Hyperlipoproteinemias · Dyslipidemias, led by Eli Lilly.

Drug pageSolbinsiran: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 23, 20223 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly31 open or runningphase 2since Feb 23, 2022Nov 24, 2020Mar 2027phase 2 · NCT07269210
  • Named in Eli Lilly’s own pipeline as Solbinsiran, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 24, 2020First study: phase 1 study in DyslipidemiasFirst studyNCT04644809 · 74 enrolled · United States
  2. Feb 23, 2022Phase 2 study in DyslipidemiasNCT05256654 · 205 enrolled · United States, Argentina, Canada and more
  3. Aug 6, 2023Named solbinsiranINNProposed as its International Nonproprietary Name in WHO's List 129 · before, LY3561774
  4. Nov 26, 2025Phase 2 study in HypertriglyceridemiaNCT07269210 · 60 planned · United States, Canada, China and more

Ahead

  1. Mar 2027Primary completion: phase 2 study in HypertriglyceridemiaNCT07269210

TargetBeta

“LY3561774 (Solbinsiran) is a GalNAc-conjugated mRNA silencing agent that specifically targets ANGPTL3 expression in the liver.”company, read by Claude · source

Other programs on ANGPTL3

ProgramCompanyFurthest phaseStudies
SHR-1918Jiangsu HengRui Medicinephase 38
VSA003rulevisirna-therapeutics-hk-limitedphase 32
EDP167ruleeddingpharm-zhuhai-co-ltdphase 23

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07269210Hypertriglyceridemia · United States, Canada, China and more2RecruitingMar 202760
NCT05256654Dyslipidemias · United States, Argentina, Canada and more2CompletedMar 4, 2024205
NCT04644809Dyslipidemias · United States1CompletedMay 17, 202274

How it is read

Names in the registry

  • “LY3561774”, 2 entries
  • “Solbinsiran”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.